Benzimidazole derivatives as modulators of IgE

• US 20050075343A1
• Filed: 09/28/2004
• Published: 04/07/2005
• Est. Priority Date: 05/22/1998
• Status: Abandoned Application

• Current Assignee: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
• Original Assignee: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
• Inventors: Campbell, Michael G., Major, Michael W., Sircar, Jagadish C., Richards, Mark L.
• Application Number:
  US10/951,515
• Publication Number:
  US 20050075343A1
• Time in Patent Office: Days
• US Class Current: 514/252.60
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/4184 condensed with carbocyclic rings, e.g. benzimidazoles
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

This invention relates to a family of benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy, asthma, or any diseases where IgE is pathogenic.

Claims

1. A pharmaceutical composition for treating an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds:

2. The pharmaceutical composition of claim 1, wherein the substituent is selected from the group consisting of alkyl, aryl, CF₃, CH₃, OCH₃, OH, CN, CONH₂, CONHR, CONR₁R₂, COOR, and COOH.

3. The pharmaceutical composition of claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

4. The pharmaceutical composition of claim 3, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β

₂-adrenergic agonist, a long-acting β

₂-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

5. The pharmaceutical composition of claim 1, wherein the compound is selected from the group consisting of:

6. A method for treating an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of claim 1.

7. The method of claim 6, further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

8. The method of claim 7, wherein said additional ingredient is selected from the group consisting of a short-acting β

₂-adrenergic agonist, a long-acting β

₂-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

9. The method of claim 6, wherein the compound is selected from the group consisting of:

10. A method for treating asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of claim 1.

11. The method of claim 10 further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

12. The method of claim 11, wherein said additional ingredient is selected from the group consisting of a short-acting β

₂-adrenergic agonist, a long-acting β

₂-adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

13. The method of claim 10, wherein the compound is selected from the group consisting of:

14. A pharmaceutical composition for treating an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds:

Genus B,